About
Bradford
  HIV/AIDS
Articles
  Alternative
Therapies
  HIV/AIDS
Videos
  HIV/AIDS
Links
  HIV/AIDS
News

Introduction:
Positively Positive
- Living with HIV
  Out
About
HIV
  Resume/
Curriculum Vitae:
HIV / AIDS Involvements
  Biography   HIV/AIDS
News Archive
HIV/AIDS News spacer.gif Bradford McIntyre spacer.gif
spacer.gif
   



Johns Hopkins - www.hopkinsmedicine.org

New Evidence That Genetic Differences May Help Explain Inconsistent Effectiveness
Of Anti-Hiv Drug

Study reveals likely differences in processing among individuals, areas of the body

Fast Facts
  • The drug tenofovir is approved to treat and prevent HIV infection orally, and it is being investigated as a potential prophylactic drug that could be used topically.
  • A study finds that the drug is processed differently by different cell types, suggesting that not all topical uses would have the same effectiveness.
  • The study also reveals that common genetic variations may render the drug ineffective for some patients.

July 9, 2015 - Research with human tissue and cells suggests that genetic variations, in addition to failure to comply with treatment regimens, may account for some failures of an anti-HIV drug to treat and prevent HIV infection.

In a report described online today in the journal EBioMedicine, investigators at Johns Hopkins found that tenofovir, marketed as Viread, is processed differently according to cell location, so that if the drug is eventually marketed as a topical gel, it could work differently depending on whether it is applied to the vagina or the rectum. 

Tenofovir has been approved since 2001 by the U.S. Food and Drug Administration to treat HIV. It is also a component of Truvada, a drug that was approved in 2012 as an oral prophylactic for use in preventing HIV infection. 

“If confirmed by further studies, our results suggest that in the future, before prescribing tenofovir to a patient, a doctor could order genetic testing and know in advance if it works, and prescribe a different drug if it won't,” says Namandje Bumpus, Ph.D., associate professor of medicine at the Johns Hopkins University School of Medicine. 

Bumpus and her colleagues focused their research on a search for the human enzymes that convert tenofovir from its original form to an activated one that combats HIV. Previous studies had revealed that the key to such activation is the addition of two molecules known as phosphate groups, she says.

To their surprise, says Bumpus, they learned that the enzyme that added the second phosphate to activate the drug in the blood and vaginal tissues, pyruvate kinase, was different from that which performed the second activation step in the colorectal tissues, known as creatine kinase.

In further experiments, the research team sequenced the genes of 142 women who had participated in a clinical trial of tenofovir to look for genetic variations that might have affected the function of pyruvate kinase, creatine kinase or the enzyme that performed the first activation step in all of the cells, adenylate kinase 2. They found 71 such variants, several of which a computer model predicted would make the enzyme ineffective. In all, 8 percent of the women had genetic variants that were likely to make them unable to convert tenofovir to its activated form.

“Tenofovir has been shown in trials to be very effective, so when it doesn’t work, researchers and clinicians tend to assume the individual just wasn’t taking the drug as directed,” Bumpus says. “That is probably true in most cases, but in others, it’s possible that genetic variation is actually at fault.”  

The team's next step, Bumpus says, will be to design a clinical trial to confirm the association between specific variants and how well the drug works.

Other authors on the paper are Julie M. Lade, Elaine E. To and Craig W. Hendrix, all of the Johns Hopkins University School of Medicine.

The study was funded by the National Institute of Allergy and Infectious Diseases (grant numbers UM1AI068633, UM1AI068615, UM1AI106707, UM1AI068613 and P30 AI094189), the Johns Hopkins University Center for AIDS Research, and the National Institute of General Medical Sciences (grant number R01 GM103853).

###

Related Stories:

On the Web:


Source: Johns Hopkins Medicine

For the Media

Contacts:

Shawna Williams
410-955-8236
shawna@jhmi.edu

Catherine Kolf
443-287-2251
ckolf@jhmi.edu

Vanessa McMains
410-502-9410
vmcmain1@jhmi.edu


For more HIV and AIDS News visit...

Positively Positive - Living with HIV/AIDS:
HIV/AIDS News


...positive attitudes are not simply 'moods'

Site Map

Contact Bradford McIntyre.

Web Design by Trevor Uksik
uks.jpg

Copyright © 2003 - 2024 Bradford McIntyre. All rights reserved.

DESIGNED TO CREATE HIV & AIDS AWARENESS

spacer.gif